Johnson & Johnson

Strategic intent

Following the spin-off of its consumer health business, Johnson & Johnson is a global healthcare company focused on developing and delivering pharmaceuticals and medical technology through its two core segments: Innovative Medicine and MedTech. [1, 10, 17]

Key market signals

• 2026-04: Acquired Atraverse Medical, a medical device company developing tools for left-heart access, to bolster its MedTech portfolio. [31]
• 2025-11: Acquired Halda Therapeutics for $3.05 billion, gaining a pipeline of novel cancer therapies designed to overcome drug resistance. [31, 43]
• 2025-01: Acquired Intra-Cellular Therapies for $14.6 billion, significantly expanding its neuroscience portfolio with the approved drug Caplyta for schizophrenia and bipolar disorder. [33, 37]
• 2024-05: Acquired Proteologix for $850 million to add bispecific antibody treatments for atopic dermatitis to its immunology pipeline. [1]
• 2024-04: Announced the $13.1 billion acquisition of Shockwave Medical to strengthen its MedTech division with innovative cardiovascular device technology. [1, 31]

Financial health

• Full-Year 2025 Revenue: $94.2 billion. [29, 11]
• Full-Year 2025 Net Income: $26.804 billion. [30, 13]
• Full-Year 2024 Revenue: $88.82 billion. [1, 21]

Impact & compliance

Legal & risks

Johnson & Johnson faces significant legal risk from over 67,000 lawsuits alleging its talc-based products caused cancer. [22] Within the last 24 months, the company's strategic attempts to resolve this liability through a subsidiary's bankruptcy (a "Texas Two-Step" maneuver) have been repeatedly rej

Classifications

🔒 Proprietary analysis

Proprietary Analysis — available with full access

Want the full analysis?

Get access to strategic fit scoring, cultural fit analysis, full forensic detail, and alignment dimensions.